• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Cantor Fitzgerald Sees Over 65% Upside for Zynerba Pharmaceuticals

October 11, 2017


Cantor Fitzgerald's Elemer Piros recently upgraded shares of Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) to 'Overweight' alongside a price target of $17.00 per share. With an analyst average price target of $12.83 per share, Piros' price target is the highest out of the analysts we track that cover Zynerba.


With a last trade price of $10.25, this ZYNE price target represents over 65% potential upside. This bullish call is due to assumptions that Zynerba's ZYN002 treatment for Fragile X syndrome will be a commercial success if the drug makes it to market. 


“Based on the positive Phase 2 FXS results, we are encouraged by the potential for ZYN002 to treat the disease and have assessed the risk-adjusted opportunity for the drug,” Piros told Benzinga. “With an annual price assumption of $45,000 (U.S.) and $32,000 (EU), ZYN002 could reach combined peak sales of $1.5 billion, in our calculation.” Additionally, "Cantor Fitzgerald estimates Zynerba will finish 2018 with roughly $73 million in cash on its balance sheet."


Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.



Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.